Wall Street Wire
Market Leaders: Silexion’s Ilan Hadar Discusses Preclinical Milestones in KRAS-Driven Cancer Treatment, Market Momentum and Financing
Silexion Therapeutics* (NASDAQ: SLXN) is making strides in oncology with its RNAi-based treatment, SIL-204, targeting KRAS-driven cancers. In an interview on Market Leaders, CEO Ilan Hadar discussed the company’s recent breakthroughs and market activity. During the interview, Hadar highlighted that SIL-204 has shown promising preclinical
